Meta-Analysis Study on Kidney Cancer Utilizes Novel Techniques to Identify Biomarkers

The survival rates of patients with kidney cancer largely depend on identifying biomarkers. The identification of these biomarkers can help determine a course of treatment. A recent study, published in JAMA, compares data from 6 clinical trials and reported in 9 publications. The report examined how biomarkers and other factors may be associated with favorable outcomes.

“Study responses were pooled using a random-effects meta-analytic model to overcome complexities of such subgroup-level analyses within the individual trials studied. Unlike in a fixed-effect model where scientists can assume a common treatment effect across studies, a random-effects model allows for the assumption that treatment effect might vary by trial.” Read more here.

(Source: Cytel, 2021)